As the United States biotechnology industry continues to expand, the sector’s financial outlook continues its gradual improvement. In 2024, investors are providing increased funding to United States biotechs. That said, more stringent approval criteria are in place. Newer companies, and those without concrete clinical trial data, may find it difficult to obtain their research and operations funding.
Venture capital investments, along with follow-on funding, have been especially strong in 2024. Mergers and acquisitions also continue at an impressive pace. Although these are encouraging trends, initial public offerings (or IPOs) haven’t yet returned to normal levels. Larger-scale economic issues can also fuel a climate of uncertainty.
Read the full article here: https://laexaminer.com/leen-kawas-discusses-3-financial-issues-biotech-leaders-should-address-in-2024/
Comments